Biogen Inc. (BIIB) – A Detailed Look At Valuations

DENNER ALEXANDER J, Director, added 38,000 shares of Biogen Inc. (BIIB) to its portfolio at the rate of $231.24 per share valuing $8,787,120 on May 02. The insider has now 643,000 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Biogen Inc. (BIIB) was $233.23. Currently, the 1st Resistance Point for this stock is $235.26, with a 2nd Resistance Point sitting at $237.29. Meanwhile, this company’s stock has a 1st Support Level at $230.70 and a 2nd Support Level at $228.17. Biogen Inc. (BIIB) stock has lost -$6.94, or -2.89%, in the past five days. In the last full month, these shares have gained $1.81, or 0.78%. In the past three months, this stock’s price has risen by $7.57, or 3.35%. This year-to-date, Biogen Inc. (BIIB) shares have lost -$67.69, or -22.49%.

Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Biogen Inc. (BIIB) stock, Hold % of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .”

With 184,447 K shares outstanding, this company currently has a market capitalization of $42,599,880K. Biogen Inc. (BIIB) generates $13,453 M in annual sales, amounting to annual net income of $4,431 M. This stock has generated a 1-Year Total Return of -31.56%, a 3-Year Total Return of -20.08%, and a 5-year Total Return of -25.52%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.

In the most recently-reported fiscal quarter, which ended in Jun-19, Biogen Inc. (BIIB) reported earnings of $9.15 per share. Wall Street analysts, on average, were expecting the company to report earnings of $7.53 per share, representing a 1.62 difference and 21.52% surprise. In the previous quarter ending in Mar-19, the reported earnings of $6.98 represented a 0.11 difference from the consensus estimate calling for $6.87 per share, which was a 1.66% surprise.

For the current fiscal quarter, which is set to end in 09/2019, the average earnings estimate is $8.20 per share. This estimate came from a total of 26 Wall Street Analysts. Of those market experts, the high estimate was $9.16 and the low estimate was $7.34. In the year-ago quarter, Biogen Inc. (BIIB) generated per-share earnings of $7.40. If the analysts are correct about the current quarter’s earnings, the growth will be +10.81% .

Turning our focus now to insider trading activity, there have been 15 purchases (16,111 shares in total) and 5 sale (1,226 shares in total) in the last 3 months. In the last 6 months, there have been 27 insider buys amounting to 49,750 shares and 17 insider sales amounting to 18,571 shares. In the past full year, 41 insider purchases were made (involving 75,218 shares) and 40 insider sell-offs equivalent to 30,489 shares.

Moving onto liquidity, Biogen Inc. (BIIB) has a Current Ratio of 2.32, a Quick Ratio of 2.04 and a Cash Ratio of 1.07. Looking at this company’s capital structure, its Total Debt to Total Equity is 45.53, its Total Debt to Total Capital is 31.28, and its Total Debt to Total Assets is now 23.47. Looking even further ahead into the future, its Long-Term Debt to Equity is 45.53 and its Long-Term Debt to Total Capital is 31.28.